ReviewOncology research2026
Navigating the Tumor Microenvironment in Colorectal Liver Metastasis: Barriers to Therapy and Emerging Opportunities.
Review in Oncology research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Myeloid-derived suppressor cells in colorectal cancer: mechanisms of immunosuppression, therapy resistance and therapeutic targeting.Frontiers in cell and developmental biology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Liver metastases from colorectal cancer (CRC) are a primary cause of poor patient prognosis, closely linked to the liver's unique tumor microenvironment (TME). Compared to primary tumors, research on the TME of liver metastases remains insufficient. This review systematically summarizes recent advances in TME research concerning colorectal liver metastases (CRLM), emphasizing its organ-specific characteristics, pivotal role in tumor progression, and influence on treatment response. We delve into the intricate cellular components of the TME-including tumor-associated macrophages, cancer-associated fibroblasts, and myeloid-derived suppressor cells-and non-cellular constituents such as the extracellular matrix and soluble factors. Furthermore, we explore the multifaceted mechanisms which the TME drives CRLM progression through establishing pre-metastatic niches, facilitating cancer cell colonization, mediating immune evasion, and inducing drug resistance. Additionally, we evaluate therapeutic strategies targeting the TME, including opportunities and challenges in remodeling cellular components, modulating the extracellular matrix, and developing combination therapies. Ultimately, this review aims to provide theoretical foundations and novel insights for developing more effective anti-metastatic therapies, with the goal of improving the prognosis for CRLM patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.